Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | PPM1D | O15297 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21307043 | 1.00 | THRB (0.35) | THRBMEN1KMT2APPM1D | |
| SCHEMBL20696859 | 1.00 | THRB (0.35) | THRBMEN1KMT2APPM1D | |
| SCHEMBL3735012 | 1.00 | THRB (0.35) | THRBMEN1KMT2APPM1D | |
| SCHEMBL3735009 | 1.00 | THRB (0.35) | THRBMEN1KMT2APPM1D | |
| SCHEMBL3735003 | 1.00 | THRB (0.35) | THRBMEN1KMT2APPM1D | |
| SCHEMBL24677027 | 0.96 | PPM1D (0.34) | PPM1D | |
| SCHEMBL12629186 | 0.96 | PPM1D (0.34) | PPM1D | |
| SCHEMBL29754849 | 0.96 | PPM1D (0.34) | PPM1D | |
| SCHEMBL31748003 | 0.96 | PPM1D (0.34) | PPM1D | |
| SCHEMBL30152746 | 0.96 | PPM1D (0.34) | PPM1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250084092-A1 | ANNULATED PYRIDAZINE COMPOUND | NICO THERAPEUTICS, INC. | 2025-03-13 | — | — | US | disclosed |
| CN-118234711-A | Cyclopyridazine compounds | 尼科治疗有限公司 | 2024-06-21 | — | — | CN | disclosed |
| EP-4375274-A1 | ANNULATED PYRIDAZINE COMPOUND | Nico Therapeutics, Inc. (US) | 2024-05-29 | — | — | EP | disclosed |
| WO-2023003002-A1 | ANNULATED PYRIDAZINE COMPOUND | アステラス製薬株式会社 | 2023-01-26 | — | — | WO | disclosed |
| WO-2003051877-A1 | 2-SUBSTITUTED PYRROLO[2.1-A]ISOQUINOLINES AGAINST CANCER | BAYER CORPORATION (US) | 2003-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250084092-A1 | ANNULATED PYRIDAZINE COMPOUND | NLRP3, NLRP1, PYCARD | THRB 4712/4885MEN1 3252/4885KMT2A 2883/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.